OR WAIT null SECS
Comprehensive Clinical Development (Comprehensive), a strategic clinical research company providing site services for Phase l through IV clinical trials, today announced recent designation as a Quintiles Prime Site, a distinction that gives Comprehensive an enhanced role in global clinical research and testing of new and more effective medicines.
As a Quintiles Prime Site, Comprehensive has the opportunity to be first in line for access to new industry-sponsored clinical trials available through Quintiles. Comprehensive joins a select group of organizations across North and South America, Europe, Africa and Asia, and is the first non-academic, non-hospital based organization awarded this status.
Comprehensive was selected because of its deep experience in delivering high-quality data, rapid study start-up expertise and its access to substantial patient populations across multiple therapeutic areas, including psychiatry, oncology, neurology and endocrinology. Comprehensive will also provide access to research participants through its well-established group of sites and therapeutic networks.
“We are honored to be recognized as a Prime Site and continue growing our longstanding relationship with Quintiles,” said Jack McGovern, CEO, Comprehensive. “We look forward to sharing in their continued success as we address the industry’s demand to streamline clinical research and provide new drugs to patients faster.”
"Comprehensive’s dedication to timeliness and quality, combined with their strong patient relationships and delivery quality, will enhance our ability to recruit patients quickly and efficiently to provide greater value for our customers,” said Lindy Jones, Senior Vice President, Integrated Site Services, Quintiles. “We look forward to a successful relationship with Comprehensive.”